# Reducing Frailty for Older Cancer Survivors Using Supplements II

> **NCT06068543** · PHASE2 · RECRUITING · sponsor: **University of Rochester** · enrollment: 118 (estimated)

## Conditions studied

- Frailty
- Inflammation

## Interventions

- **DRUG:** Epigallocatechin-3-Gallate (EGCG)
- **DRUG:** Microcrystalline cellulose (MCC)
- **DIETARY_SUPPLEMENT:** Ascorbic Acid (Vitamin C)

## Key facts

- **NCT ID:** NCT06068543
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-25
- **Primary completion:** 2030-01-01
- **Final completion:** 2030-12-31
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06068543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06068543, "Reducing Frailty for Older Cancer Survivors Using Supplements II". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06068543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*